A prospective, blinded analysis of A-PROTEIN (recoverin or CAR protein) levels in pediatric patients with central nervous system tumors

Peter Manley, Xiaochun Li, Christopher Turner, Susan Chi, Mary Ann Zimmerman, Christine Chordas, Amanda Gordon, Amanda Baker, Nicole J. Ullrich, Liliana Goumnerova, Karen Marcus, Ken Hoffman, Mark W. Kieran

Research output: Contribution to journalArticle

Abstract

Background. Abnormal expression of A-PROTEIN has been identified in a number of tumors including carcinoma of the lung, breast, colon, prostate, and cervix. Brain tumors have been reported to express high plasma levels of A-PROTEIN, suggesting that it may be of significant diagnostic and prognostic value. Procedure. This prospective study evaluated the sensitivity and specificity of A-PROTEIN levels in pediatric brain tumor patients. Patients included those with newly diagnosed disease pre- and post-surgery, during treatment, during routine follow-up, and at recurrence or progression. A total of 154 A-PROTEIN levels from 54 patients were evaluated. Results. For patients without evidence of disease, 42% had normal A-PROTEIN levels, 35% were elevated, and 23% were equivocal. For patients with stable disease, 53% demonstrated normal A-PROTEIN levels, 19% were elevated, and 28% were equivocal. For patients with progressive disease, 53% had normal A-PROTEIN levels, 35% were elevated, and 12% were equivocal. The sensitivity was 35% and the specificity was 50%. A correlation of increased A-PROTEIN levels in patients with increased disease in glial tumors was also identified. Conclusions. A-PROTEIN levels were not predictive of disease status in children with most brain tumors. However, in patients with glial tumors there was a correlation with increased disease and elevated A-PROTEIN levels. This could represent variability of A-PROTEIN during growth, development, or tumor cell origin and needs further evaluation.

Original languageEnglish (US)
Pages (from-to)343-347
Number of pages5
JournalPediatric Blood and Cancer
Volume53
Issue number3
DOIs
StatePublished - Sep 2009

Keywords

  • A-PROTEIN
  • Brain tumor
  • CAR
  • Pediatric
  • Recoverin
  • Surrogate marker

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'A prospective, blinded analysis of A-PROTEIN (recoverin or CAR protein) levels in pediatric patients with central nervous system tumors'. Together they form a unique fingerprint.

  • Cite this

    Manley, P., Li, X., Turner, C., Chi, S., Zimmerman, M. A., Chordas, C., Gordon, A., Baker, A., Ullrich, N. J., Goumnerova, L., Marcus, K., Hoffman, K., & Kieran, M. W. (2009). A prospective, blinded analysis of A-PROTEIN (recoverin or CAR protein) levels in pediatric patients with central nervous system tumors. Pediatric Blood and Cancer, 53(3), 343-347. https://doi.org/10.1002/pbc.22017